Active	Status	Sponsor type	Region	Phase	Filter
3 Active 1 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
gildeuretinol (ALK-001) / Alkeus
SAGA, NCT03845582: Phase 3 Study of ALK-001 in Geographic Atrophy	Completed	3	200	US	ALK-001 oral capsule, C20-D3-Retinyl Acetate, C20 Deuterated vitamin A, Placebo oral capsule	Alkeus Pharmaceuticals, Inc.	Geographic Atrophy, Age Related Macular Degeneration, AMD, Atrophy, Geographic	07/23	06/24
TEASE, NCT02402660: Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease	Enrolling by invitation	2	160	US	ALK-001, C20-D3-Retinyl Acetate, C20 Deuterated vitamin A, Placebo	Alkeus Pharmaceuticals, Inc.	Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)	06/26	11/26
TEASE-EXT, NCT04239625: Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)	Active, not recruiting	2	200	US	ALK-001, C20-D3-Retinyl Acetate, C20 Deuterated vitamin A	Alkeus Pharmaceuticals, Inc.	Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)	12/26	12/26
Lebers Hereditary Optic Neuropathy Therapy / Alkeus
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
gildeuretinol (ALK-001) / Alkeus
SAGA, NCT03845582: Phase 3 Study of ALK-001 in Geographic Atrophy	Completed	3	200	US	ALK-001 oral capsule, C20-D3-Retinyl Acetate, C20 Deuterated vitamin A, Placebo oral capsule	Alkeus Pharmaceuticals, Inc.	Geographic Atrophy, Age Related Macular Degeneration, AMD, Atrophy, Geographic	07/23	06/24
TEASE, NCT02402660: Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease	Enrolling by invitation	2	160	US	ALK-001, C20-D3-Retinyl Acetate, C20 Deuterated vitamin A, Placebo	Alkeus Pharmaceuticals, Inc.	Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)	06/26	11/26
TEASE-EXT, NCT04239625: Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)	Active, not recruiting	2	200	US	ALK-001, C20-D3-Retinyl Acetate, C20 Deuterated vitamin A	Alkeus Pharmaceuticals, Inc.	Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)	12/26	12/26
Lebers Hereditary Optic Neuropathy Therapy / Alkeus
No trials found